论文部分内容阅读
目的评价罗格列酮对非酒精性脂肪肝(NAFLD)的作用,观察其疗效。方法选择60例NAFLD患者随机分组,对照组30例,罗格列酮组30例,观察体重指数(BMI)、空腹血糖(FBG)、空腹胰岛素含量(FINS)、胰岛素抵抗指数(H0MA-IR)、三酰甘油(TG)、总胆固醇(TC)、谷丙转氨酶(ALT)、谷草转氨酶(AST)等变化。并比较治疗前后肝脾CT比值改变,比较两组疗效。结果与对照组对比,罗格列酮组治疗后,FPG、FINS、HOMA-IR、TC、TG、ALT、AST明显降低,肝脾CT比值明显升高,均有统计学意义(P<0.05)。结论罗格列酮能改善NAFLD患者的血糖和血脂,改善胰岛素抵抗,逆转肝脂肪变性和NAFLD所致的肝脏酶谱升高。
Objective To evaluate the effect of rosiglitazone on non-alcoholic fatty liver disease (NAFLD) and to observe its curative effect. Methods Sixty NAFLD patients were randomly divided into control group (n = 30) and rosiglitazone group (n = 30). Body mass index (BMI), fasting blood glucose (FBG), fasting insulin (FINS), insulin resistance index (H0MA-IR) , Triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and other changes. The changes of CT ratio of liver and spleen before and after treatment were compared, and the curative effect was compared between the two groups. Results Compared with the control group, the levels of FPG, FINS, HOMA-IR, TC, TG, ALT and AST in the rosiglitazone group were significantly decreased and the ratios of liver and spleen CT were significantly increased (all P <0.05) . Conclusion Rosiglitazone can improve blood glucose and blood lipids in NAFLD patients, improve insulin resistance, reverse hepatic steatosis and liver enzymes caused by NAFLD increased.